The most popular peptide healing stack. How to dose, time, and combine BPC-157 and TB-500 for injury recovery.
BPC-157 and TB-500 are the two most commonly combined healing peptides because they work through complementary mechanisms. BPC-157 promotes angiogenesis (new blood vessel formation), modulates nitric oxide, and provides localized healing when injected near an injury. TB-500 promotes systemic healing by regulating actin, stimulating cell migration, and reducing inflammation throughout the body.
Together, they address tissue repair from multiple angles: BPC-157 builds the blood supply to damaged tissue while TB-500 mobilizes the repair cells that use that blood supply. Research in animal models suggests the combination may produce faster and more complete healing than either peptide alone.
Inject subcutaneously near the injury site, morning and evening. For systemic/gut healing, inject in the abdomen.
Inject subcutaneously anywhere (abdomen, thigh, arm). TB-500 is systemically active regardless of injection site.
Loading phase: 4-6 weeks at the doses above. Maintenance: After initial healing, reduce TB-500 to once weekly and BPC-157 to once daily for another 2-4 weeks. Total duration: 6-10 weeks for most injuries.
Yes. BPC-157 and TB-500 can be drawn into the same syringe and injected simultaneously. However, many practitioners prefer separate injections because BPC-157 benefits from localized delivery near the injury site, while TB-500 is effective anywhere. If you have a systemic condition (gut healing, general inflammation), combining them in a single abdominal injection is practical.
Calculate your doses: BPC-157 calculator | TB-500 calculator
The rationale for pairing them is that they are studied for different steps of the same repair process rather than duplicating each other.
BPC-157 is a pentadecapeptide, a 15 amino acid sequence derived from a protein found in gastric juice. Preclinical work has focused on angiogenesis, the formation of new blood vessels, and on nitric oxide pathway effects. The practical framing is blood supply to a damaged area.
TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring protein involved in actin regulation. Actin is a structural protein central to cell movement, so the studied mechanism concerns cell migration into a damaged area and the reorganization of tissue during remodeling.
Blood supply and cell migration are complementary rather than redundant, which is the entire argument for running them together. It is worth being clear about the evidence level: this reasoning comes from preclinical and animal research. Neither compound has completed human clinical trials for these uses, and the combination specifically has not been studied as a combination in humans.
The dosing frequencies in the protocol above are not arbitrary, and the difference traces to half-life. BPC-157 has a half-life of roughly 4 hours, while TB-500 sits closer to 24 hours. That is a six-fold difference, and it is why one is commonly dosed once or twice daily while the other is dosed a few times per week.
TB-500 protocols also typically use a loading phase followed by a maintenance phase. The reasoning is that the longer half-life allows levels to accumulate, so a higher initial frequency establishes a baseline that a lower maintenance frequency can then sustain. BPC-157 protocols generally do not use loading, because with a 4 hour half-life very little carries over between doses. The half-life chart shows where both sit relative to other compounds.
Injection load. BPC-157 twice daily plus TB-500 twice weekly is roughly 16 injections a week. That is a meaningful commitment, and it makes site rotation a real requirement rather than a suggestion. See the injection sites guide for why repeated use of one spot causes problems.
Reconstitution volumes will differ. Because the two are dosed in different amounts, the water volume that produces clean syringe math for one will usually not do so for the other. Calculate each vial separately rather than defaulting to the same volume for both.
Cost accumulates differently. A compound dosed twice daily burns through vials far faster than one dosed twice weekly, even when the per-dose amount is smaller. Run both through the protocol builder to see weekly cost rather than comparing vial prices.
Verification is the unaddressed variable. Both are research-supply compounds, so vial contents are not verified for identity, purity, or concentration by any regulatory standard. Every number on this page assumes the label is accurate.